Physician profile
Randolph Oliver Schultz
NPI 1215991518
$3,921.76
in general payments reported to CMS, 2019-2025
36 companies · $720 in 2025
The $720 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $216 · 2021: $588 · 2022: $838 · 2023: $1,000 · 2024: $255 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,975.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,202.46 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $379.44 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $368.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $236.23 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $174.04 | 2021-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.72 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $155.30 | 2019-2025 | Trintellix |
| Pfizer INC. | $126.91 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $126.18 | 2019-2025 | Verquvo, Gardasil 9, Vaqta |
| Glaxosmithkline, LLC. | $123.71 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amarin Pharma, INC. | $83.07 | 2020-2021 | |
| Bausch Health US, LLC | $76.28 | 2019-2023 | Aplenzin, Wellbutrin |
| Currax Pharmaceuticals LLC | $72.18 | 2022-2025 | Contrave, Onzetra Xsail |
| Bayer Healthcare Pharmaceuticals INC. | $64.04 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.20 | 2019-2025 | Relistor |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randolph Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.